Face Mask Regulations by Australia’s TGA

Non-sterile face masks are regulated as medical devices under the Therapeutic Goods Act of 1989. Importation, distribution or exportation of any goods are required to be included in the ARTG (Australian Register of Therapeutic Goods).
Australia’s TGA regulations for cosmetics with sunscreens

In Australia, cosmetics that contain sunscreens (UV filters) are regulated by the Health Authority Therapeutic Goods Administration (TGA). The cosmetic can only be approved for market if it meets the legal definition of either ‘therapeutic’ or ‘cosmetic’.
FDA introduces Medical Device User Fee Amendments for Fiscal year 2021

Food and Drug Administration updates lists of Medical Device User Fees for Fiscal year 2021. and increases cost of certain MD submissions.
Brazil’s Health Authority requires Registration Holders to send daily information to ANVISA regarding drugs necessary in COVID-19 Pandemic

Companies that hold drug registrations must provide Anvisa daily information about the manufacture, import and distribution of anesthetics, sedatives, neuromuscular blockers and adjuvant agents, among other drugs used to maintain the lives of patients infected with the new coronavirus (Sars-CoV-2).
China’s NMPA introduces new guidance for COVID-19 drug clinical trials

China’s National Medical Product Administration (NMPA) released on July 2020 a guideline focused on the emergency approval of the new COVID-19 virus drugs and vaccines for sponsors and researchers.
Brazil’s Anvisa produces new committee for the accelerated submission of COVID-19 related clinical trials.

Anvisa has established a Committee for Evaluation of Clinical Studies, Registration and Post-registration of Drugs for prevention or treatment of Covid-19.
Brazil’s Anvisa publishes Service Orientation (OS) that may provide simplification of clinical trial applications (DDCM)

Anvisa pusblishes Service Orientation (OS) 88/2020 provides details on procedures for reviewing documents required for submission of the Clinical Drug Development Dossier (DDCM) and changes that potentially impact the quality or safety of experimental drugs, active BE drugs or placebos.
FDA holds up UDI enforcement for Class I device

The FDA delays the enforcement of Unique Device Identification (UDI) for Class I medical devices and will come in action from 24 September 2022.
Colombia’s Invima modifies administration measures due to COVID-19 pandemic

Invima changes the transitional administrative measures under Resolution 2020012926 of 3rd April 2020 due to COVID-19
FDA resumes on-site domestic inspection

The United States Food and Drug Administration lifts halt on domestic routine surveillance facility inspections from week of July 20, 2020.
TGA’s expectation on hosting remote inspection during COVID-19 pandemic

Therapeutic Goods Administration (TGA) publishes the Good Manufacturing Practices (GMP) approach for oversees manufacturers to assist manufacturers who may undergo remote inspection.
China’s NMPA Publishes the “Cosmetic Supervision and Administration Regulation”

On June 29,2020 The National Medical Products Administration (NMPA) published a new cosmetic regulation known as the “Cosmetic Supervision and Administration Regulation”.